Technology Appraisals
It is important to note that the advice contained within
the guidance does not override or replace the individual responsibility of health professionals to make
appropriate decisions in the circumstances of their individual patients, in consultation with the patient
and/or guardian or carer. This would, for example, include situations where individual patients have
other conditions or complications that need to be taken into account in determining whether the NICE
guidance is fully appropriate in their case.
The following technology appraisals have been endorsed during 2012-13.
Information on technology appraisals endorsed in previous years can be found using the links at
the bottom and left of this page.
Fully Endorsed
May 2012
- TA250 - Eribulin for the treatment of locally
advanced or metastatic breast cancer
- TA252 - Telaprevir for the treatment of genotype 1 chronic hepatitis
C
- TA253 - Boceprevir for the treatment of genotype 1 chronic hepatitis
C
- TA251 - Dasatinib, nilotinib and standard-dose imatinib for
the first-line treatment of chronic myeloid leukaemia (including part review of
TA70)
- TA254 Fingolimod for the treatment of relapsing remitting multiple
sclerosis
- TA 255 - Cabazitaxel for the 2nd-line treatment of hormone refractory
metastatic prostate cancer
April 2012
Endorsed With Caveats
None
Not Endorsed as Applicable to Northern Ireland
None
